<DOC>
	<DOCNO>NCT01187303</DOCNO>
	<brief_summary>The purpose trial determine efficacy ofatumumab patient relapse nodular lymphocyte predominant Hodgkin lymphoma ( NLPHL ) .</brief_summary>
	<brief_title>Ofatumumab Nodular Lymphocyte Predominant Hodgkin Lymphoma ( NLPHL )</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>relapse nodular lymphocyte predominant hodgkin lymphoma age 18 75 review diagnosis experience pathologist major organ dysfunction classical hodgkin lymphoma CD20 antibody treatment within last 6 month prior enrollment chronic current infectious disease requirering systemic antibiotic past current malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>